Altmetric – Lung function in idiopathic pulmonary fibrosis - extended analyses of the IFIGENIA trial

You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.

Title	Lung function in idiopathic pulmonary fibrosis - extended analyses of the IFIGENIA trial
Published in	Respiratory Research, October 2009
DOI	10.1186/1465-9921-10-101
Pubmed ID	19860915
Authors	Jürgen Behr, Maurits Demedts, Roland Buhl, Ulrich Costabel, Richard PN Dekhuijzen, Henk M Jansen, William MacNee, Michiel Thomeer, Benoit Wallaert, Francois Laurent, Andrew G Nicholson, Eric K Verbeken, Johny Verschakelen, CDR Flower, Stefano Petruzzelli, Paul De Vuyst, van den JMM Bosch, Eulogio Rodriguez-Becerra, Ida Lankhorst, Marco Sardina, Gabrielle Boissard
Abstract	The randomized placebo-controlled IFIGENIA-trial demonstrated that therapy with high-dose N-acetylcysteine (NAC) given for one year, added to prednisone and azathioprine, significantly ameliorates (i.e. slows down) disease progression in terms of vital capacity (VC) (+9%) and diffusing capacity (DLco) (+24%) in idiopathic pulmonary fibrosis (IPF). To better understand the clinical implications of these findings we performed additional, explorative analyses of the IFGENIA data set.

View on publisher site Alert me about new mentions

Mendeley readers

The data shown below were compiled from readership statistics for 61 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country	Count	As %
Netherlands	1	2%
India	1	2%
Peru	1	2%
Belgium	1	2%
Spain	1	2%
United States	1	2%
Unknown	55	90%

Demographic breakdown

Readers by professional status	Count	As %
Student > Bachelor	10	16%
Student > Master	9	15%
Other	8	13%
Student > Ph. D. Student	7	11%
Student > Doctoral Student	4	7%
Other	15	25%
Unknown	8	13%

Readers by discipline	Count	As %
Medicine and Dentistry	32	52%
Biochemistry, Genetics and Molecular Biology	3	5%
Business, Management and Accounting	3	5%
Pharmacology, Toxicology and Pharmaceutical Science	3	5%
Agricultural and Biological Sciences	2	3%
Other	6	10%
Unknown	12	20%

Attention Score in Context

This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 30 May 2014.

All research outputs

#4,462,965

of 17,358,590 outputs

Outputs from Respiratory Research

#518

of 2,188 outputs

Outputs of similar age

#45,813

of 196,673 outputs

Outputs of similar age from Respiratory Research

of 22 outputs

Altmetric has tracked 17,358,590 research outputs across all sources so far. This one has received more attention than most of these and is in the 74th percentile.

So far Altmetric has tracked 2,188 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.8. This one has done well, scoring higher than 76% of its peers.

Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 196,673 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 76% of its contemporaries.

We're also able to compare this research output to 22 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 95% of its contemporaries.

Lung function in idiopathic pulmonary fibrosis - extended analyses of the IFIGENIA trial

About this Attention Score

Mentioned by

Citations

Readers on

Mendeley readers

Geographical breakdown

Demographic breakdown

Attention Score in Context